Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 307,959 | 264,566 | 576,021 | 508,882 |
| Operating expenses | ||||
| Cost of product sales | 28,316 | 20,734 | 53,107 | 41,126 |
| Research and development | 81,555 | 77,951 | 158,423 | 156,216 |
| Selling, general and administrative | 160,252 | 133,507 | 331,271 | 259,877 |
| Total operating expenses | 270,123 | 232,192 | 542,801 | 457,219 |
| Income from operations | 37,836 | 32,374 | 33,220 | 51,663 |
| Interest income, net | 7,990 | 7,243 | 16,045 | 15,144 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's R&D?
- Acadia Pharmaceuticals (ACAD) reported R&D of $81.56M in Q2 2026.
- How has Acadia Pharmaceuticals's R&D changed year-over-year?
- Acadia Pharmaceuticals's R&D increased by 4.6% year-over-year, from $77.95M to $81.56M.
- What is the long-term trend for Acadia Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's R&D has grown at a 8.3% compound annual growth rate (CAGR), from $239.42M to $328.8M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Acadia Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude